Autobahn Therapeutics

Autobahn Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California, developing regenerative medicines for central nervous system (CNS) disorders. The company pairs a proprietary brain-targeting chemistry platform - which creates orally administered small-molecule prodrugs designed to cross the blood-brain barrier - with validated human biology and biomarker-driven development strategies. Its pipeline includes elunetirom (its lead clinical program, being developed for indications such as bipolar depression), ABX-101 (a next-generation CNS-active S1P molecule), and ABX-003. Autobahn is backed by venture investors including Canaan Partners and Insight Partners. This profile is maintained in the API Evangelist network; the company does not currently publish a public developer API, so this record captures company identity and published web properties only.

Autobahn Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Biotechnology, Central Nervous System, and Neuroscience.

Autobahn Therapeutics’ developer surface includes engineering blog, support, and 8 more developer resources.

🌐 Visit website 📡 Source on GitHub

11.9/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiopharmaceuticalBiotechnologyCentral Nervous SystemNeuroscienceDrug DevelopmentRegenerative MedicineSmall MoleculeClinical StageHealthcare

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 11.9/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 1.3 / 20

Commercial Clarity 2.1 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/autobahn-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support

Support

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

Company 5

The organization behind the API

Website

About

Blog

Careers

LinkedIn

Other 2

Properties that don't map to a standard resource type

Pipeline

Pipeline

Science

Science

Source (apis.yml)

aid: autobahn-therapeutics
name: Autobahn Therapeutics
description: Autobahn Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California, developing
  regenerative medicines for central nervous system (CNS) disorders. The company pairs a proprietary brain-targeting chemistry
  platform - which creates orally administered small-molecule prodrugs designed to cross the blood-brain barrier - with validated
  human biology and biomarker-driven development strategies. Its pipeline includes elunetirom (its lead clinical program,
  being developed for indications such as bipolar depression), ABX-101 (a next-generation CNS-active S1P molecule), and ABX-003.
  Autobahn is backed by venture investors including Canaan Partners and Insight Partners. This profile is maintained in the
  API Evangelist network; the company does not currently publish a public developer API, so this record captures company identity
  and published web properties only.
url: https://raw.githubusercontent.com/api-evangelist/autobahn-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
- insight-partners
x-tier: stub
x-tier-reason: portfolio-lead
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Biopharmaceutical
- Biotechnology
- Central Nervous System
- Neuroscience
- Drug Development
- Regenerative Medicine
- Small Molecule
- Clinical Stage
- Healthcare
image: https://www.autobahntx.com/wp-content/themes/autobahn/assets/images/logo.svg
apis: []
common:
- type: DomainSecurity
  url: security/autobahn-therapeutics-domain-security.yml
- type: Website
  url: https://www.autobahntx.com
  name: Autobahn Therapeutics
- type: About
  url: https://autobahntx.com/about-us/
  name: About Us
- type: Pipeline
  url: https://autobahntx.com/our-pipeline/
  name: Our Pipeline
- type: Science
  url: https://autobahntx.com/our-science/
  name: Our Science
- type: Blog
  url: https://autobahntx.com/news/
  name: News
- type: Careers
  url: https://autobahntx.com/careers/
  name: Careers
- type: Support
  url: https://autobahntx.com/contact-us/
  name: Contact Us
- type: PrivacyPolicy
  url: https://autobahntx.com/privacy-policy/
  name: Privacy Policy
- type: LinkedIn
  url: https://www.linkedin.com/company/autobahn-therapeutics-inc/
  name: LinkedIn
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence